Memory Disorders Clinical Trials

Featured Study

The PEACE-AD trial is testing whether prazosin, an FDA-approved drug for high blood pressure, can effectively treat frequent disruptive agitation in people with moderate to severe Alzheimer’s disease (AD). This is a Phase IIb multicenter, randomized, double-blind, placebo-controlled study looking to recruit approximately 186 participants with AD complicated by disruptive agitation residing in an long term care facility (LTC) or in the home with full-time caregiving. To be eligible for PEACE-AD, a person must be experiencing one or more of the following behaviors frequently (approximately 5 times per week): a) irritability and anger outbursts, b) physically and/or verbally aggressive behavior, c) physically resistive to necessary care, and/or d) pressured motor activity (e.g., pressured pacing). The total duration of participation is approximately 16 weeks. To learn more about this clinical trial opportunity enrolling at the Stanford Neuroscience Health Center, contact the Study Coordinator, Amanda Ng, at (650) 485-9560 or amandang@stanford.edu.

Stanford Memory Disorders Clinical Trials

Active, recruiting:

Sponsor: Alzheimer's Disease Cooperative Study (PeaceAD Study)
Intervention
: Prazosin
Indication
: Probable or possible AD and disruptive agitation
Clinicaltrials.gov identifier: 
NCT03710642
PI
: Victor Henderson, MD and Sharon Sha, MD
Contact:
 Amanda Ng, amandang@stanford.edu

Active, not recruiting:

Sponsor: Genentech (Lauriet Study)
Intervention
: RO7105705 (Monoclonal antibody binding to tau)
Indication
: Moderate AD
Clinicaltrials.gov identifier: NCT03828747
PI
: Sharon Sha, MD
Contact: 
Jenn Gaudioso, jenn.gaudioso@stanford.edu

Sponsor: Biogen (Tango Study)
Intervention
: BIIB092 (Monoclonal antibody binding to tau)
Indication
: MCI/Mild AD
Clinicaltrials.gov identifier: 
NCT03352557
PI
: Sharon Sha, MD
Contact:
 Viktoriya Bourakova, viktoriya.bourakova@stanford.edu

Sponsor: Genentech (Tauriel Study)
Intervention
: RO7105705 (Monoclonal antibody binding to tau)
Indication
: MCI/Mild AD
Clinicaltrials.gov identifier: 
NCT03289143
PI
: Sharon Sha, MD
Contact:
 Jenn Gaudioso, jenn.gaudioso@stanford.edu

Sponsor: Cortexyme (Gain Study) 
Intervention
: COR388 (Gingipain inhibitor) 
Indication
: Mild to Moderate AD
Clinicaltrials.gov identifier: 
NCT03823404
PI
: Sharon Sha, MD
Contact:
 Amanda Ng, amandang@stanford.edu

Completing, not recruiting:

Sponsor: Novartis (Generations II Study)
Intervention:
 CNP520 (Active BACE-1 Inhibitor)
Target Population:
 Cognitively Unimpaired APOEHomozygotes or Amyloid Positive Heterozygotes
Clinicaltrials.gov identifier: 
NCT03131453
PI
: Sharon Sha, MD
Contact:
 Amanda Ng, amandang@stanford.edu

Sponsor: Novartis (Generations I Study)
Intervention:
 CAD106 (Induces Active Antibody without activating Aβ-reactive T cells) and CNP520 (BACE-1 Inhibitor)
Target Population:
 Cognitively Unimpaired APOEHomozygotes
Clinicaltrials.gov identifier: 
NCT02565511
PI
: Sharon Sha, MD
Contact:
 Amanda Ng, amandang@stanford.edu

Upcoming: (Recruiting by invitation only: participants who were previously enrolled in aducanumab trials) 

Sponsor: Biogen (Embark Study)
Intervention
: Aducanumab (Monoclonal antibody binding to amyloid)
Indication
: MCI/Mild AD
Clinicaltrials.gov identifier: 
NCT04241068
PI
: Sharon Sha, MD
Contact:
 Jenn Gaudioso, jenn.gaudioso@stanford.edu

Clinical trials contacts

memoryresearch@stanford.edu
(650) 724-8736

Sharon Sha, MD, MS
Clinical Assistant Professor, Neurology & Neurological Sciences
Director, Memory Disorders Clinical Trials
ssha1@stanford.edu
(650) 723-5072